An observational study in Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer, sponsored by National Cancer Centre, Singapore. Recruiting at 3 sites in 3 countries. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by National Cancer Centre, Singapore · Observational
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.
This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.
This study will be a multi-center observational study and will enroll patients with advanced EGFR exon 20 insertion mutated NSCLC.
The study will include patients recruited from countries across Asia, including sites in, but not limited to - Hong Kong, Korea, Singapore, Taiwan and Thailand. There will be approximately 20-30 sites recruiting for the study. In Singapore, sites may include National Cancer Centre Singapore (NCCS), National University Hospital (NUH) and Tan Tock Seng Hospital (TTSH).
Approximately 600 patients will be enrolled retrospectively.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 600 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →National Cancer Centre, Singapore is the lead sponsor of 116 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with advanced EGFR exon 20 insertion mutated NSCLC.
Exclusion Criteria:
Overall survival (OS)
Time from diagnosis to death.
Time frame: Up to 10 years.
Duration of therapy (DOT)
Time from start of treatment regimen to end of treatment regimen.
Time frame: Up to 10 years.
Real-world progression-free survival (PFS)
Time from start of treatment regimen to disease progression or death.
Time frame: Up to 10 years.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Centre, Singapore